Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]

• Lukasiewicz, E.
• Hellstrand, K.
• Westin, J.
• Ferrari, C.
• Neumann, A.U.
• Pawlotsky, J.M.
• Schalm, S.W.
• Zeuzem, S.
• Veldt, B.J.
• Hansen, B.E.
• Verhey-Hart, E.
• Lagging, M.
• , et al.

January 2007
Article